Exelixis (EXEL) stock analysis: 14x 2026E EPS vs. sector, cabozantinib growth, zanzalintinib upside, and FDA/Q4 catalysts.

BOULDER, Colo., Jan. 8, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of ...

Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Atumelnant ...

Taurine from octopus and squid neutralizes oxygen radicals that destroy perovskite solar cells, then regenerates to provide ...

Teresa Ribera has completed her first year at the helm of the European Commission’s competition directorate (“DG COMP”). It was a year in which ...

Johnson & Johnson announced positive topline results from the Phase 2b JASMINE study of adults living with systemic lupus erythematosus and the initiation of a Phase 3 program. The JASMINE study met ...

Shares of Corvus Pharmaceuticals rose after its investigational drug soquelitinib showed positive results in an early-stage trial in atopic dermatitis patients. The stock surged 50% to $12.10 in ...

Imagine shining a flashlight into a material and watching the light bend backward—or in an entirely unexpected direction—as ...

WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the cheap S&P 500 stocks to invest in now. On January 12, Bristol-Myers Squibb announced positive topline results from its Phase 3 SCOUT-HCM clinical ...